Access to Biosimilars in Federal Hospitals in Addis Ababa: Assessment of the National Medicines Regulatory Framework and Healthcare Professionals’ Perspectives

Simple item page
dc.contributor.advisorTsige Gebre-Mariam
dc.contributor.authorShimelis Ayele
dc.date.accessioned2026-06-22T15:51:36Z
dc.date.available2026-06-22T15:51:36Z
dc.date.issued2025-05-13
dc.description.abstractThe introduction of biopharmaceuticals brought remarkable clinical outcomes, particularly in the treatment and management of challenging chronic diseases. However, the high cost of originator biologics limits their accessibility. The adoption of biosimilars offers a cost-effective alternative, reducing healthcare expenditures and improving patient access to biologic therapies. Despite their potential benefits, the national regulatory framework and lack of understanding and confidence of healthcare professionals hinder the accessibility and uptake of essential biosimilars.
dc.identifier.urihttps://etd.aau.edu.et/handle/123456789/8421
dc.language.isoen_US
dc.publisherAddis Ababa University
dc.subjectAccess
dc.subjectBiologics
dc.subjectBiosimilars
dc.subjectRegulatory Framework
dc.subjectHealthcare Professionals’ Perception
dc.titleAccess to Biosimilars in Federal Hospitals in Addis Ababa: Assessment of the National Medicines Regulatory Framework and Healthcare Professionals’ Perspectives
dc.typeThesis

Files

Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
Shimelis Ayele.pdf
Size:
1.9 MB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed to upon submission
Description:
Download

Collections

Pharmacognosy